• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novartis AG Common Stock (NY:NVS)

    154.25 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Mar 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,426
    Open 154.25
    Bid (Size) 154.10 (200)
    Ask (Size) 154.21 (600)
    Prev. Close 154.25
    Today's Range 154.25 - 154.25
    52wk Range 97.72 - 170.46
    Shares Outstanding N/A
    Dividend Yield 2.59%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income ↗
    Via Chartmill
    News headline image
    VYMI: This International ETF Could Help You Earn Higher Dividends ↗
    If you want international stock exposure with a chance for higher dividend yields, this Vanguard ETF could be a good buy. 
    Via The Motley Fool
    Topics ETFs

    Performance

    YTD
    +11.3%
    +11.3%
    1 Month
    -2.5%
    -2.5%
    3 Month
    +16.5%
    +16.5%
    6 Month
    +20.8%
    +20.8%
    1 Year
    +42.0%
    +42.0%

    More News

    Read More
    News headline image
    3 ETFs to Avoid as Oil Shock Hits Markets ↗
    Via MarketBeat
    Topics ETFs
    News headline image
    Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
    Via MarketMinute
    Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals ↗
    Via Chartmill
    News headline image
    Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
    Via Finterra
    Topics Economy Intellectual Property Lawsuit
    News headline image
    Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
    Via MarketBeat
    Topics ETFs
    News headline image
    Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement ↗
    Via Benzinga
    Topics Lawsuit
    News headline image
    Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
    Via MarketMinute
    Topics Economy Intellectual Property
    News headline image
    Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio? ↗
    Via The Motley Fool
    Topics Intellectual Property Retirement
    News headline image
    Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
    Via MarketMinute
    News headline image
    A Look Into Novartis Inc's Price Over Earnings ↗
    Via Benzinga
    News headline image
    Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
    Via The Motley Fool
    Topics ETFs Stocks
    News headline image
    Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise ↗
    Via Benzinga
    News headline image
    Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
    Via MarketMinute
    Topics Artificial Intelligence Economy

    Frequently Asked Questions

    Is Novartis AG Common Stock publicly traded?
    Yes, Novartis AG Common Stock is publicly traded.
    What exchange does Novartis AG Common Stock trade on?
    Novartis AG Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novartis AG Common Stock?
    The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
    What is the current price of Novartis AG Common Stock?
    The current price of Novartis AG Common Stock is 154.25
    When was Novartis AG Common Stock last traded?
    The last trade of Novartis AG Common Stock was at 03/12/26 07:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.